Join
Live feed
·
PRReleasevia Quantisnow
ALX Oncology Holdings Inc. logo

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ALXO· ALX Oncology Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALXO (ALX Oncology Holdings Inc.) and more on Quantisnow.